As we welcome the fall season, it’s time for our September edition of Editors’ Picks, a monthly collection of articles hand-picked by the editors of the eight scientific journals published by the AACR. This month, articles span from an assessment of a first-in-class antibody-drug conjugate targeting the antigen CD205 in xenograft models, to results from a clinical trial evaluating the dual inhibition of VEGFR2 and MET in patients with advanced solid tumors. Read on to learn about this month’s selections, which are freely available for a limited time.Read More
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry.
Panelists in the “Addressing Advocacy at the Bench: Implementing Change” session held Sunday …
The 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved kicked off Friday evening in San Francisco with a passionate call to fight cancer disparities on every front, from socioeconomic to biological.
“Everyone in this room is united in our goal to eliminate cancer health disparities,” said conference cochair Phyllis Pettit Nassi, MSW, manager of Special Populations and Native American Outreach at Huntsman Cancer Institute in Salt Lake City. “Medical research powers our ability to treat our patients. Conferences such as this, where we unite as a community, fuel hope that we can improve the lives of our patients.”Read More
Immunotherapy is a form of cancer treatment that helps a patient’s own immune system recognize and attack cancer cells. Research on different types of immunotherapy has exploded over the past decade, and such approaches have proven to be successful for many patients. However, challenges remain, including a lack of response in some patients, development of resistance, and difficulties using certain immunotherapies in solid tumors.Read More
Today, the American Association for Cancer Research (AACR) released its ninth annual Cancer Progress Report. The report highlights how research largely supported by federal investments in the National Institutes of Health (NIH) is spurring improvements in public health and innovative breakthroughs across the spectrum of cancer care.Read More
Cancer researchers often focus on developing novel treatments or combining therapies in new ways, all with the goal of lengthening survival for patients. But some cancer research has a different goal: to reduce the amount and intensity of treatment patients receive while maintaining equally good cancer outcomes. In the summer 2019 issue of Cancer Today, digital editor Kate Yandell writes about the challenges and successes of this approach, called treatment de-escalation.Read More
The AACR Project Genomics Evidence Neoplasia Information Exchange (AACR Project GENIE) is a unique registry that aggregates, harmonizes, and links clinical-grade cancer genomic data with clinical outcomes from tens of thousands of cancer patients. AACR Project GENIE recently released its sixth data set, increasing the database to nearly 70,000 de-identified genomic records. The database now has information spanning more than 80 major cancer types, including data from more than 11,000 patients with lung cancer, over 9,700 patients with breast cancer, and nearly 7,000 patients with colorectal cancer.Read More
Cancer is very complex, and the tools that we need to understand how it develops and progresses come from many different scientific fields. Integrative Molecular Epidemiology, known as IME, brings together epidemiologists, data scientists, and basic scientists, along with many clinical specialties, to jointly study cancer from different angles. By its very nature, IME is a truly transdisciplinary field that unites researchers from varied backgrounds. The American Association for Cancer Research (AACR) supports this field through a longstanding working group.Read More
Since 2011, immunotherapy has emerged as an exciting new approach to cancer treatment that is yielding unprecedented, durable responses for patients with an increasingly diverse array of cancer types. Much …Read More
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to efficiently answer important clinical, research, and regulatory questions around oncology treatments and outcomes. RWD can come from a variety of sources, including medical claims data, electronic health records, patient-reported outcomes, and product or disease registry data. Real-world evidence (RWE) is clinical evidence generated from these data.
While the randomized controlled trial remains the gold standard for gathering clinical evidence for regulatory use, RWE can provide critical insights in situations where such trials may be difficult to complete. This is especially relevant in oncology, where personalized medicine approaches are leading to increasingly smaller patient populations that necessitate new strategies for efficient drug development.Read More